WO2024259147 - DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF
National phase entry:
Publication Number
WO/2024/259147
Publication Date
19.12.2024
International Application No.
PCT/US2024/033877
International Filing Date
13.06.2024
Title **
[English]
DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF
[French]
PEPTIDES CIBLANT DLL3 ET CONSTRUCTIONS ASSOCIÉES
Applicants **
MARIANA ONCOLOGY INC.
Inventors
METCALF III, Chester A.
HUANG, Chunhui
WAN, Murray
BRUTON, Thomas C.
MA, Zhong
WU, Lihua
COSTANTE, Roberto
BRANCA, Danila
RICARDO, Alonso
Priority Data
63/508,208
14.06.2023
US
63/554,470
16.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5431 | |
| EPO | Filing, Examination, Granting | 43186 | |
| Japan | Filing, Examination, Granting | 3461 | |
| South Korea | Filing, Examination, Granting | 4694 | |
| USA | Filing, Examination, Granting | 16190 |
Total:
72,962
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.[French]
La présente divulgation concerne des fractions de ciblage telles que des peptides qui peuvent se lier à DLL3. La divulgation concerne également des constructions de ciblage, qui peuvent comprendre une fraction de ciblage fixée, par l'intermédiaire d'un lieur facultatif, à un agent chélatant pour l'association d'un chargement. L'invention concerne également des procédés de fabrication des constructions et des formulations de celles-ci. L'invention concerne en outre des méthodes d'utilisation des constructions et/ou des formulations de celles-ci pour traiter des sujets, par exemple, pour traiter ou prévenir le cancer.